GlobalData on MSN
Compass’ psilocybin shows six-month durability in Phase III trial
Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.
The goal: a personal assistant whose memory is a graph you own, queryable by any MCP-aware client (the bundled harness, Claude Code, Claude Desktop, Cursor, …).
Feel free to contribute and also submit your AI tools on altern.ai for free Welcome to Awesome AI Tools! Dive into my curated list of AI list, featuring top generative ai tools and LLMs. Eager to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results